4.8 ML berahyaluronidase alfa-pmph 2000 UNT/ML / pembrolizumab-pmph 165 MG/ML Injection
- RxCUI
- 2723771
- RxNorm name
- 4.8 ML berahyaluronidase alfa-pmph 2000 UNT/ML / pembrolizumab-pmph 165 MG/ML Injection
- Display name
- 4.8 ML berahyaluronidase alfa-pmph 2000 UNT/ML / pembrolizumab-pmph 165 MG/ML Injection
- Full name
- 4.8 ML berahyaluronidase alfa-pmph 2000 UNT/ML / pembrolizumab-pmph 165 MG/ML Injection
- Term type
- SCD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:46
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761467 | Keytruda Qlex | pembrolizumab and berahyaluronidase alfa-pmph | 351(a) | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| KEYTRUDA QLEX | PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH | Merck Sharp & Dohme LLC | 097d166f-b73b-41d3-9b37-7653cd2a0c41 | 2026-07-10 | Warnings, Adverse reactions | 2723771 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 097d166f-b73b-41d3-9b37-7653cd2a0c41 | 4.8 ML berahyaluronidase alfa-pmph 2000 UNT/ML / pembrolizumab-pmph 165 MG/ML Injection | SCD | 14 | These highlights do not include all the information needed to use KEYTRUDA QLEX safely and effectively. See full prescribing information for KEYTRUDA QLEX. KEYTRUDA QLEX ™ (pembrolizumab and berahyaluronidase alfa-pmph) injection, for subcutaneous use Initial U.S. Approval: 2025 | 20260512 |
| 097d166f-b73b-41d3-9b37-7653cd2a0c41 | pembrolizumab-pmph 790 MG / berahyaluronidase alfa-pmph 9600 UNT in 4.8 ML Injection | PSN | 14 | These highlights do not include all the information needed to use KEYTRUDA QLEX safely and effectively. See full prescribing information for KEYTRUDA QLEX. KEYTRUDA QLEX ™ (pembrolizumab and berahyaluronidase alfa-pmph) injection, for subcutaneous use Initial U.S. Approval: 2025 | 20260512 |
| 097d166f-b73b-41d3-9b37-7653cd2a0c41 | pembrolizumab-pmph 790 MG / berahyaluronidase alfa-pmph 9600 UNT per 4.8 ML Injection | SY | 14 | These highlights do not include all the information needed to use KEYTRUDA QLEX safely and effectively. See full prescribing information for KEYTRUDA QLEX. KEYTRUDA QLEX ™ (pembrolizumab and berahyaluronidase alfa-pmph) injection, for subcutaneous use Initial U.S. Approval: 2025 | 20260512 |